(Q36839736)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17547509%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

review article

1 reference

title

Vaccine strategies against human cytomegalovirus infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17547509%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17547509%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Jie Zhong

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17547509%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

1 June 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17547509%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anti-infective Therapy

31 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17547509%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17547509%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17547509%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

449-459

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17547509%20AND%20SRC:MED&resulttype=core&format=json

Genetic content of wild-type human cytomegalovirus

31 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Encouraging prospects for immunisation against primary cytomegalovirus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Direct measurement of CD4+ and CD8+ T-cell responses to CMV in HIV-1-infected subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Cytomegalovirus (CMV)-specific CD4+ T lymphocyte immune function in long-term survivors of AIDS-related CMV end-organ disease who are receiving potent antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Natural killer cells in antiviral defense: function and regulation by innate cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Virus-specific antibody responses to human cytomegalovirus (HCMV) in human immunodeficiency virus type 1-infected persons with HCMV retinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Passive Immunization during Pregnancy for Congenital Cytomegalovirus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Safety and immunogenicity of the Towne strain cytomegalovirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Is there a formula for an effective CMV vaccine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Human cytomegalovirus vaccine: time to look for alternative options.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Development of a cytomegalovirus vaccine: lessons from recent clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Optimization of DNA immunization against human cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Human cytomegalovirus-specific immunity following haemopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Progress made towards the development of a CMV peptide vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Replication of cytomegalovirus in human epitheloid diploid cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Development of novel vaccine strategies against human cytomegalovirus infection based on subviral particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Protein delivery by subviral particles of human cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Ex vivo expansion of human cytomegalovirus-specific cytotoxic T cells by recombinant polyepitope: implications for HCMV immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Molecular analysis of herpesviral gene products recognized by protective cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Murine cytotoxic T cell response specific for human cytomegalovirus glycoprotein B (gB) induced by adenovirus and vaccinia virus recombinants expressing gB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

Severe herpesvirus infections in an adolescent without natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.449

21 January 2018

Identifiers

DOI

10.1586/14787210.5.3.449

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17547509%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference